Rigel director sells 2,500 shares for taxes

Rigel Pharmaceuticals director Kamil Ali-Jackson sold 2,500 shares of common stock at $35.00 per share in an open-market transaction.

Rhea-AI Filing Summary

Rigel Pharmaceuticals director Kamil Ali-Jackson sold 2,500 shares of common stock at $35.00 per share in an open-market transaction. After the sale, she directly holds 10,125 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025 and, according to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than for investment purposes.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares

Net Sell 1 txn

Insider Ali-Jackson Kamil

Role Director

Sold 2,500 shs ($88K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$35.00	$88K

Holdings After Transaction: Common Stock — 10,125 shares (Direct)

Footnotes (2)

1. F1. The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.
2. F2. The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes.

Key Figures

Shares sold: 2,500 shares Sale price: $35.00 per share Shares held after transaction: 10,125 shares +1 more

4 metrics

Shares sold 2,500 shares Open-market sale on 2026-06-22

Sale price $35.00 per share Price for 2,500 sold shares

Shares held after transaction 10,125 shares Direct holdings post-sale

Net shares sold 2,500 shares Net-sell direction in transaction summary

Key Terms

10b5-1 trading plan, restricted stock units, tax withholding obligations, open-market sale

4 terms

10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025."

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

restricted stock units financial

"The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rigel (RIGL) director Kamil Ali-Jackson report?

Kamil Ali-Jackson reported selling 2,500 shares of Rigel common stock at $35.00 per share. The transaction is classified as an open-market sale and was disclosed on a Form 4 insider trading report for the company.

Why did Rigel (RIGL) director Kamil Ali-Jackson sell 2,500 shares?

The 2,500 shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units. The filing states the shares were not sold for investment purposes, indicating the sale was tied to compensation-related tax requirements.

Was the Rigel (RIGL) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes that the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. Such plans pre-schedule trades, helping separate routine portfolio or tax management from discretionary market-timing decisions.

How many Rigel (RIGL) shares does Kamil Ali-Jackson hold after the sale?

After selling 2,500 shares, Kamil Ali-Jackson directly holds 10,125 shares of Rigel common stock. This post-transaction holding figure comes from the Form 4 and shows she retains a continuing equity position in the company following the tax-related sale.

What price did the Rigel (RIGL) director receive for the sold shares?

The 2,500 Rigel common shares were sold at $35.00 per share. This per-share price is disclosed in the Form 4 transaction details and applies to the full block of shares involved in the reported open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali-Jackson Kamil

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		S(1)(2)		2,500	D	$35	10,125	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

2. The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes.

	/s/ Raymond Furey (Attorney-in-Fact)	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)